Name | Relationship | Address | Signature | Signature date | CIK |
---|---|---|---|---|---|
Basta Steven L | President and CEO, Director | C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK | /s/ Steven L. Basta | 2025-09-26 | 0001417397 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PHAT | Common Stock | Options Exercise | $0 | +90K | $0.00 | 90K | Sep 25, 2025 | Direct | ||
transaction | PHAT | Common Stock | Tax liability | -$564K | -48.4K | -53.75% | $11.66 | 41.6K | Sep 25, 2025 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PHAT | Performance Shares | Options Exercise | $0 | -90K | -25% | $0.00 | 270K | Sep 25, 2025 | Common Stock | 90K | $0.00 | Direct | F2, F3 |
Id | Content |
---|---|
F1 | Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. |
F2 | Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. |
F3 | On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved. |